Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients

Abstract

There is a clinical need for reliable biomarkers for lung cancer that permit early diagnosis of the disease and provide prediction of histological phenotype. A prospective study design was used with a study population of patients with suspected lung cancer. Blood samples were collected from 17 patients with histologically confirmed squamous cell lung carcinoma, 17 individuals with adenocarcinoma, and 17 control individuals who did not subsequently have a diagnosis of lung cancer or any other cancer. Blood plasma samples were analysed for their lipid profiles using liquid chromatography coupled with high resolution mass spectrometry. Data were analysed using multivariate statistical methods. There was good separation between histological subtypes and control groups and also between individuals with a subsequent diagnosis of adenocarcinoma and squamous cell carcinoma (sensitivity 80%, specificity 83%, Q 2 =0.70). Alterations in the levels of different classes of lipids including triglycerides (TGs), phosphatidylinositols (PIs), phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), free fatty acids, lysophospholipids and sphingolipids were observed in squamous carcinoma and adenocarcinoma lung cancer patients when compared with control patients. In conclusion, this study has identified candidate lipid biomarkers of non-small cell lung cancer patients which may be helpful to indicate the tumour subtype and to differentiate them from patients who do not have lung cancer. Measuring these biomarkers has the potential to improve diagnosis in patients with suspected lung cancer and risk stratification in screening.

Diagnosis of malignant pleural mesothelioma from pleural fluid by Fourier transform-infrared spectroscopy coupled with chemometrics

“…Moreover, we have also found a higher triglyceride and cholesterol ester amount in the MPM pleural fluid group. Recently, Ravipati et al 65 demonstrated the elevated plasma triglyceride level in lung cancer patients, which is in agreement with our results. Lower membrane fluidity and higher membrane order in the MPM group were also indicated from the lower bandwidth value and lower band position value of CH 2 antisymmetric stretching band.…”

Transcriptional analysis of adipose tissue during development reveals depot-specific responsiveness to maternal dietary supplementation

“…A product ion prediction tool from Lipidmaps (Lipid MS Predict) was use to assist spectral interpretation. The identities of selected isobaric lipid species were subsequently elucidated by generating MS/MS spectra (nominal mass) using the same LC method with a Thermo Scientific LTQ Velos ion trap mass spectrometer using equivalent electrospray source settings and with a collision energy of 40 19 .…”

A Systematic Evaluation of Blood Serum and Plasma Pre-Analytics for Metabolomics Cohort Studies

“…It currently provides a wide range of new opportunities for the development of biomarkers of medical interest with current applications in toxicology [7], cancer [8,9,10], cardiovascular disease [11,12], prediction of treatment outcomes [13,14,15] or “pharmacometabonomics” [16,17], and more recently metabolic modelling of the patient journey in a clinical environment [18,19]. Untargeted metabolomics is typically achieved using a range of analytical technologies, such as mass spectrometry (MS) and nuclear magnetic resonance (NMR) [20,21,22], resulting in the monitoring of hundreds to thousands of molecular species potentially involved in the molecular fingerprints of diseases.…”